Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the stocks on Jim Cramer’s radar recently. When Cramer was asked about the ...
Detailed price information for Silence Therapeutics Plc ADR (SLN-Q) from The Globe and Mail including charting and trades.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue ...
Incyte on Tuesday raised its annual sales forecast for Jakafi after the cancer drug helped the company post third-quarter results above Wall Street estimates.
Barchart on MSN
1 Growth Stock Under $100 to Buy Before It Soars
Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for ...
Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...
TipRanks on MSN
Swedish Orphan Biovitrum’s Phase 3 Study on Pacritinib: A Potential Game-Changer for ...
Swedish Orphan Biovitrum Ab (($GB:0MTD)) announced an update on their ongoing clinical study. Swedish Orphan Biovitrum is conducting a Phase 3 ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
A doer, motivator, creator and adventurer, Meredith will be best remembered as upbeat, outspoken and confident, with a remarkable drive to excel at anything she did.
Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update.
Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈